C-reactive protein in cardiovascular risk assessment: a review of the evidence

Area of Science:

• Biomarkers
• Cardiovascular Disease Research
• Inflammation Studies

Background:

• C-reactive protein (CRP) is a key inflammatory biomarker.
• CRP is associated with coronary heart disease, inflammation, and metabolic syndrome.
• Existing data on CRP's predictive value in cardiovascular risk assessment present conflicting interpretations.

Purpose of the Study:

• To evaluate the role of C-reactive protein (CRP) in enhancing cardiovascular risk prediction.
• To determine if CRP measurement can reclassify individuals within existing risk stratification models.
• To assess the implications of CRP-based risk reclassification for primary prevention strategies.

Main Methods:

• Analysis of large-scale prospective cohort trial data.
• Evaluation of CRP measurement in conjunction with the Framingham risk score.
• Assessment of risk reclassification in primary prevention cohorts.

Main Results:

• CRP measurement shows potential to add predictive accuracy to the Framingham risk score.
• Conflicting interpretations exist regarding the utility of CRP data in large trials.
• CRP can reclassify patients from low or intermediate Framingham risk to higher-risk categories.

Conclusions:

• C-reactive protein (CRP) measurement can enhance cardiovascular risk prediction, particularly in primary prevention.
• CRP facilitates the identification of individuals who may benefit from more intensive pharmacologic interventions.
• Further clarification is needed on the interpretation of CRP data in diverse patient populations.